KOSDAQCosmetics217480

SD Biotechnologies

₩499 0.00%2026-11-18 close
Market Cap
₩54.8B
Turnover
₩0
Volume
0 shares
Shares out.
110M
PER
—
PBR
2.1×
EPS
-₩61
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses Narrow as Sales Fall; Listing Status in Dispute

Press reports say the exchange ordered delisting in October 2026 and the company has sought an injunction, while operating losses have kept narrowing as sales decline.

  1. 1

    Listing status: Press reports say the exchange decided on delisting in October 2026, and the company applied for an injunction to suspend that decision.

  2. 2

    Sales: Revenue fell for three consecutive years from 2023 to 2025, and third-quarter 2026 sales of KRW 5.19 billion were down 24.5% year on year.

  3. 3

    Profitability: Operating loss narrowed from KRW 41 billion in 2022 to KRW 6.32 billion in 2025, and the third-quarter 2026 operating loss of KRW 954 million was the smallest of the last five quarters.

  4. 4

    Balance sheet: The debt ratio fell from 1,897.5% in 2022 to 60.5% in 2025, and press reports said consolidated total liabilities were KRW 4.4 billion at the end of June 2026.

  5. 5

    Product concentration: In the first quarter of 2026, mask packs accounted for 63% of sales and eye patches for 22%, with overseas sales at 48%.

02

Business structure

SD Biotechnologies was founded in 2008 as a cosmetics manufacturer and listed on KOSDAQ in March 2017. Its core products are the SNP-brand mask packs and eye patches, and its portfolio also includes a food brand launched in 2022.

In the first quarter of 2026, consolidated sales were KRW 6.07 billion, of which product sales were KRW 4.84 billion and merchandise sales were KRW 1.227 billion. Mask packs generated KRW 3.196 billion, or 63% of sales, and eye patches KRW 1.103 billion, or 22%.

By region, domestic sales were KRW 3.172 billion (52%) and overseas sales were KRW 2.896 billion (48%). As of 2025 reporting, overseas sales relied mainly on duty-free channels through a Chinese distributor, and a 2026 report said the Vietnam subsidiary had no sales and was being liquidated.

China accounted for 31% of sales in the first half of 2025, but local Chinese brands and shifting consumer patterns sharply reduced China sales. The company has widened distribution to Japan through Qoo10 and to the United States through Amazon.

Among peers, it is a small-to-mid-sized, dermatology-focused brand company, with a different scale and structure from brand leaders such as Amorepacific and LG H&H or ODM manufacturers such as Cosmax and Kolmar Korea.

Since Daewon became the largest shareholder with a 72.9% stake in 2023, the cosmetics business has been positioned as a healthcare growth initiative, so its direction depends on the parent company's strategy.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.9B-₩1.7B−25.4%
2025Q4₩6.3B-₩1.6B−24.5%
2026Q1₩6.1B-₩1.1B−17.5%
2026Q2₩6.3B-₩1.4B−22.1%
2026Q3₩5.2B-₩1B−18.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩92.9B-₩41B-₩72.7B−44.2%−2349.9%1897.5%
2023₩46.9B-₩13.7B-₩4.6B−29.1%−10.5%68.8%
2024₩34.5B-₩9.2B-₩14.3B−26.8%−49.0%103.7%
2025₩30.1B-₩6.3B-₩7.4B−21.0%−25.1%60.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On an annual basis, sales fell from KRW 92.9 billion in 2022 to KRW 46.9 billion in 2023 (down 49.4% year on year), KRW 34.5 billion in 2024 (down 26.6%), and KRW 30.1 billion in 2025 (down 12.8%), declining for three consecutive years from 2023 to 2025.

Of the four years, 2022 had the largest sales and 2025 the smallest. Operating losses narrowed from KRW 41 billion in 2022 to KRW 13.7 billion in 2023, KRW 9.24 billion in 2024 and KRW 6.32 billion in 2025, so the company stayed loss-making for four consecutive years while the loss shrank.

The operating margin improved from -44.2% in 2022 to -21.0% in 2025. In 2025 the company said sales fell on weak consumer spending, but operating results improved on cost restructuring, and overall profitability rose as non-operating expenses declined after balance sheet improvements.

Net loss attributable to controlling shareholders was KRW 72.7 billion in 2022, narrowed to KRW 4.61 billion in 2023, widened to KRW 14.3 billion in 2024, and narrowed again to KRW 7.36 billion in 2025. Net loss including non-controlling interests was KRW 14.8 billion in 2024 and KRW 7.49 billion in 2025.

In 2024 the net loss was larger than the operating loss, which suggests a heavier non-operating burden. The company also exited loss-making affiliates, including the full sale of its stake in SD Platform in 2025, which removed that entity from consolidation.

The debt ratio fell from 1,897.5% in 2022 to 60.5% in 2025, and operating cash flow improved from negative KRW 15.4 billion in 2022 to negative KRW 5.14 billion in 2025, though it stayed negative in all four years.

On a quarterly basis, sales fell from KRW 6.87 billion in the third quarter of 2025 to KRW 5.19 billion in the third quarter of 2026, and operating losses over the same five quarters ran at KRW 1.75 billion, KRW 1.55 billion, KRW 1.06 billion, KRW 1.39 billion and KRW 954 million.

According to a Beauty Newsys analysis of the 2026 half-year report published in October 2026, first-half sales fell 26.6% to about KRW 12.4 billion while the operating loss narrowed to about KRW 2.4 billion. The net loss attributable to controlling shareholders over the last four quarters totals KRW 6.69 billion.

05

Industry analysis

The cosmetics industry is going through two shifts at once: reduced reliance on China and a split in consumer spending. SD Biotechnologies built its early momentum in China on SNP mask packs, but local Chinese brands and changing consumer habits have sharply reduced its China sales.

A Wisereport company comment said weak domestic and global economic conditions have kept value-for-money and value-for-price consumer trends in place.

Global beauty demand is moving toward bio-based ingredients, dermatology cosmetics and home-care devices, and the company has been criticized for not presenting a differentiated growth strategy aligned with that shift.

Listed peers in the sector split into groups: large brand portfolios such as Amorepacific, ODM manufacturers with contract-based revenue such as Cosmax and Kolmar Korea, and dermatology-focused players such as NeopharmCO.

The company's sales are concentrated in two products, mask packs and eye patches, which made it exposed to category demand changes; together they made up 85% of first-quarter 2026 sales.

An analyst at Sangsangin Securities said the cosmetics business has not yet produced meaningful synergies and that its turnaround will be a key variable for the parent's consolidated earnings. Overseas channel sales and the breadth of product categories are the indicators to watch for any industry recovery.

06

Outlook

The company and its controlling shareholder have outlined three directions.

The first is balance sheet repair: a September 2026 report said that property sales and the repayment of convertible bonds eliminated borrowings, bringing consolidated total liabilities to KRW 4.4 billion at the end of June and the debt ratio down to 15.9%. The second is a restructuring of overseas entities.

The company is reviewing consolidation of several Chinese entities spread across Shanghai and Qingdao, and the liquidation of the Indonesian entity has reportedly been completed.

The third is product and channel expansion: a 2025 report mentioned joint development of functional cosmetics with the parent and wider distribution in Japan and the United States.

Management changes include the appointment of a CEO in November 2025 and the recruitment of an external cosmetics industry executive in June 2026.

The company is also pursuing a share consolidation: its board reportedly approved combining five common shares into one, which would raise the par value per share to KRW 1,000 and cut the share count to about 21.95 million.

First-half 2026 selling, general and administrative expenses fell 22.3% year on year to KRW 8.18 billion, but the remaining task is to restore profitability by growing product sales as sales continue to decline.

After the October 2026 delisting decision, the company applied for an injunction to suspend it, and a court ruling is still pending. The company has said it will continue the cosmetics business regardless of its listing status.

The next checkpoints are therefore the injunction outcome, whether the share consolidation and trading resumption proceed, and the full-year sales trend in the 2026 annual report.

07

Valuation

PER
—
PBR
2.1×
ROE
-21.9%
EPS
-₩61
BPS
₩239
Dividend per share
₩0

At the current share price, the PER cannot be calculated because the company has posted net losses over the last four quarters. The PBR is above 1x, which means the market price carries a premium to net asset value.

Total equity was KRW 29.9 billion at the end of 2025, of which KRW 29.4 billion was attributable to controlling shareholders. Total equity was KRW 29.8 billion at the end of 2024, so it held roughly steady in 2025 despite continued losses. No dividend is being paid.

A share price above book value can be read as reflecting recovery expectations that the reported results have not yet confirmed.

However, the price may be formed under conditions tied to the listing status and whether trading resumes, which lowers how representative multiples are when compared with other listed companies.

Earnings-based multiples are hard to apply to a company with continuing operating losses, and that should be kept in mind in any peer comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Lower financial burden

The debt ratio fell from 1,897.5% in 2022 to 60.5% in 2025. A September 2026 report said consolidated total liabilities fell to KRW 4.4 billion at the end of June and borrowings were cleared.

Total equity of KRW 29.9 billion at the end of 2025 held near the 2024 level, and a free capital reduction removed the capital impairment position.

Cost efficiency and narrower losses

Operating loss narrowed from KRW 41 billion in 2022 to KRW 6.32 billion in 2025. The third-quarter 2026 operating loss of KRW 954 million was the smallest of the last five quarters. Press reports said first-half 2026 selling, general and administrative expenses fell 22.3% year on year.

Overseas channels and joint development

Overseas sales made up 48% of first-quarter 2026 sales. Products are sold on Qoo10 in Japan and Amazon in the United States. Joint development of functional cosmetics with the parent has also been reported. Overseas channels could partly offset softer domestic demand, which is a positive factor.

09

Bear factors

Sales decline continues

Sales have fallen for three consecutive years from 2023 to 2025. Third-quarter 2026 sales of KRW 5.19 billion were down 24.5% year on year. First-half 2026 sales fell 26.6% to about KRW 12.4 billion, so cost cuts have not offset the revenue decline.

Uncertain listing status

Press reports said the exchange decided on delisting in October 2026, and the company applied for an injunction against it. Reports note that the business can continue as an unlisted company even after delisting.

However, recovery in the value of shares is tied to a future return to profitability and a recovery in enterprise value.

Concentration in products and China

Mask packs made up 63% of first-quarter 2026 sales and eye patches 22%. China accounted for 31% of sales in the first half of 2025, but China sales weakened as local brands gained share. If the reliance on specific products and channels does not change, the company remains exposed to demand shifts.

10

Risk factors

Listing status and trading

A delisting decision in October 2026 was reported, and the company applied for an injunction to suspend it. The outcome will determine whether shares can trade. A share consolidation that reduces share count and raises par value is also being pursued. The company says the business will continue regardless of listing status.

Revenue concentration and demand shifts

Mask packs and eye patches made up 85% of first-quarter 2026 sales, which leaves the company sensitive to demand changes. If China sales declines and local brand competition persist, expanding the overseas share may be difficult. First-half 2026 sales fell 26.6%, and the decline continued in the third quarter.

Dependence on the controlling shareholder

The parent holds a 72.9% stake as the largest shareholder and has led management appointments and financial support. Sales of affiliates and the liquidation of overseas entities have narrowed the business scope. A change in the parent's strategy could alter both the business direction and the scale of financial support.

11

What to watch next

  1. Date to be confirmed (upon court ruling)

    The outcome of the injunction to suspend delisting. The ruling determines whether trading can resume and the conditions for minority shareholders.

  2. Around late March 2027

    Filing of the 2026 annual report. This will show whether the sales decline that began in 2023 continued in 2026 and whether the operating loss narrowed from KRW 6.32 billion in 2025.

  3. Mid-May 2027

    The first-quarter 2027 quarterly report. Compare sales and operating loss with the first quarter of 2026, which were KRW 6.07 billion and KRW 1.06 billion, to see whether the trend holds.

  4. Date to be confirmed

    Whether the share consolidation takes effect and trading resumes, and whether the consolidation of Chinese entities is disclosed.

12

Overall view

SD Biotechnologies saw sales fall for three consecutive years from 2023 to 2025 while narrowing its operating and net losses. Sales of KRW 30.1 billion in 2025 were well below KRW 92.9 billion in 2022.

On the balance sheet, the debt ratio fell from 1,897.5% in 2022 to 60.5% in 2025, and a 2026 report said borrowings were cleared at the end of June. The operating margin improved from -44.2% in 2022 to -21.0% in 2025, but operating cash flow was negative in every year from 2022 to 2025.

Sales kept declining in 2026, down 26.6% in the first half and 24.5% in the third quarter, while the third-quarter operating loss of KRW 954 million was the smallest of the last five quarters.

On the listing side, press reports said the exchange decided on delisting in October 2026, and the company applied for an injunction, so a court ruling is still pending.

Strengths include the easing of the financial burden and cost efficiency, while weaknesses include the sales decline, concentration in products and China, and uncertainty over listing status.

The next checkpoints are the injunction outcome, the full-year sales trend in the 2026 annual report, and the size of the operating loss in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kr.investing.com
  2. knnws.com
  3. m.news.nate.com
  4. cosinkorea.com
  5. comp.wisereport.co.kr
  6. innoforest.co.kr
  7. thescoop.co.kr
  8. m.news.nate.com
  9. edaily.co.kr
  10. pharm.edaily.co.kr
  11. topdaily.kr
  12. e-science.co.kr
  13. ebn.co.kr
  14. biz.newdaily.co.kr
  15. beautynury.com
  16. thebionews.net
  17. pointdaily.co.kr
  18. topstarnews.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis